PTK787对K562细胞增殖及细胞周期作用的影响(3)
 |
| 第1页 |
参见附件。
[5] Lin B，Podar K，Gupta D，et al.The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myelom a cells in the bone marrow microenvironment[J].Cancer Res，2002，62(17)：5019-5026.
[6] Roboz G J，Giles F J，List A F，et al.Phase l study of PTK787/ZK 222584.a small molecule tyrosine kinase receptor inhibitor，for the treatment of acute myeloid leukemia and myeloid ys plastic syndrome[J].Leukemia，2006，20(6)：952-957.
[7]茆勇军，李海泓，李剑峰，等.蛋白酪氨酸激酶信号转导途径与抗肿瘤药物[J].药学学报，2008，43(4)：323，334.
[8] Bold G， Buchdtmger E.PTK787/ZK 222584， a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases，impai vascular endothelial growth factor-induced responses and tumor growth after oral administration[J].Cancer Res，2000，60(8)：2178-2189.
[9] Le Coutre P， Ottmann O G， Giles F.Nilotinib formerly AMN107， a highly selective BCR-ABL tyrosine kinase inhibitor，is active in patients with imatinib resistant or intolerant accelerated-phase chronic myelogenous leukemia[J].Blood，2008，1114(1)：1834-1839.
[10] Liu Y，Poon R T，Li Q，et a1.Both antiangiogenesis and angiogenesis independent effects are responsible for hepatocellular carcinoma growth， arrest by tyrosine kinase inhibitor K787/ZK222584[J].Cancer Res，2005，65(9)：3691-3699.
[11] Zhao J，Pestell R，Guan J L.Transcriptional activation cyclin D1 promoter by FAK contributes to cell cycle progression[J].Mol Biol Cell，2001，12(1)：4066-4077.
(收稿日期：2013-03-06) (本文编辑：连胜利)
您现在查看是摘要介绍页，详见PDF附件。